Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients
Annals of Hematology · 16.07.2026 · 105 (11)
DOI: 10.1007/s00277-026-07110-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 16.07.2026. Verfasst von Nicolas Albrecht und 11 weiteren Autor:innen. Beteiligte Einrichtung: Universitair Ziekenhuis Gent, Gent, Belgium. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
The introduction of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)-targeting bispecific antibody, represents a novel therapy for patients with relapsed/refractory multiple myeloma (RRMM). Despite its promising efficacy, talquetamab is associated with distinctive adverse events (AEs), such as oral (dysgeusia, dysphagia, dry mouth) and dermatologic AEs (rashes, other skin-related symptoms, nail toxicities). These recommendations aim to develop a multidisciplinary framework for managing GPRC5D-related AEs, tailored for a wide audience that includes hematologists, oncology nurses, dieticians, and patients. A comprehensive literature review was conducted to identify current evidence and guidelines on GPRC5D-related AEs. Clinical experience from 12 Belgian healthcare professionals (6 hematologists, 4 nurses, 2 dieticians) was integrated and discussed to inform the development of practical recommendations. Data were synthesized to develop practical recommendations for managing common talquetamab-related AEs. Key AEs included dysgeusia, dry mouth, dysphagia, skin toxicities, and nail toxicities. These AEs, though mostly low-grade, impacted patient quality of life and nutritional status. Management strategies focused on dose modifications, oral care, dermatologic support, and early dietician referral. Patient education and multidisciplinary collaboration were identified as essential components of optimal supportive care. This is the first expert consensus-based set of multidisciplinary recommendations in Belgium addressing GPRC5D-related AEs. It provides practical, role-specific recommendations to support talquetamab-treated patients, improve tolerability, and optimize treatment adherence and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universitair Ziekenhuis Gent, Gent, Belgium.
- Universitaire Ziekenhuizen KU Leuven, Leuven, Belgium.
- Centre Hospitalier Universitaire de Liège, Liège, Belgium.
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
- Universitair Ziekenhuis Brussel, Jette, Belgium.
- Universitair Ziekenhuis Gent, Gent, Belgium. nicolas.kint@uzgent.be.
Zitieren
APA
Albrecht, N., Boeckx, E., Caers, J., Delaunois, S., Delforge, M., Deneve, D., Kint, N., Meuleman, N., Sarrazyn, L., Schots, R., Vanhellemont, A., & Vekemans, M. C. (2026). Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07110-0
Vancouver
Albrecht N, Boeckx E, Caers J, Delaunois S, Delforge M, Deneve D, et al. Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07110-0
BibTeX
@article{Albrecht2026,
author = {Albrecht, Nicolas and Boeckx, Eline and Caers, Jo and Delaunois, Sophie and Delforge, Michel and Deneve, Dorien and Kint, Nicolas and Meuleman, Nathalie and Sarrazyn, Louise and Schots, Rik and Vanhellemont, Anneleen and Vekemans, Marie-Christiane},
title = {Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07110-0}
}
EUVIMED